The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases

BackgroundThe inactivated quadrivalent influenza vaccine (IIV4) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) are widely administered. However, there was limited clinical evidence on the immunogenicity and safety of administration of the two vaccines in individuals with chronic dise...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wanqin Tang, Xi Lu, Zhongkui Zhu, Dan Yu, Huaxian Liu, Yufei Song, Lu Shen, Yang Yu, Yanwei Zhao, Yan Xie
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	chronic disease inactivated quadrivalent influenza vaccine 23-valent pneumococcal polysaccharide vaccine simultaneous administration immunogenicity safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1624095/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction: The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases
by: Frontiers Production Office
Published: (2025-08-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
by: Tao Huang, et al.
Published: (2024-12-01)

Immunogenicity, Safety, and Clinical Eﬀectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
by: M. M. Baranova, et al.
Published: (2022-04-01)

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
by: B. Ts. Batozhargalova, et al.
Published: (2024-09-01)

Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China
by: Jing Qiu, et al.
Published: (2025-07-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study
by: L. S. Namazova-Baranova, et al.
Published: (2023-01-01)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013-01-01)

INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: G. M. Tarasova, et al.
Published: (2018-09-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024-07-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
by: G. M. Tarasova, et al.
Published: (2020-08-01)

ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017-10-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
by: A. V. Rudakova, et al.
Published: (2019-03-01)

Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01)

Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
by: Muhammad Zain Ul Haq, et al.
Published: (2025-06-01)

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
by: Esra Çakar, et al.
Published: (2025-02-01)

Suspected adverse events following immunization associated with seperate/combined administration of 13-valent pneumococcal polysaccharide conjugate vaccine and oral pentavalent human rotavirus live attenuated vaccine in age-eligible children in a district of Shanghai
by: CHEN Jinyan, et al.
Published: (2025-03-01)

Results of Clinical Trials of the First Russian 4-valent Flu Vaccine
by: D. A. Lioznov
Published: (2018-09-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case
by: Ekaterina I. Alekseeva, et al.
Published: (2019-09-01)

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season
by: Marina Amaral de Avila Machado, et al.
Published: (2024-12-01)

Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
by: Yajun Shu, et al.
Published: (2024-12-01)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018-10-01)

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6–35 months of age in China: A randomized, double-blind, clinical trial
by: Shilei Wang, et al.
Published: (2024-12-01)

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial
by: Zhiqiang Xie, et al.
Published: (2024-12-01)

The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
by: M. S. Naumtseva, et al.
Published: (2015-08-01)

IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A TWO-YEAR FOLLOW-UP STUDY
by: M. S. Naumtseva, et al.
Published: (2017-01-01)

EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. S. Naumtseva, et al.
Published: (2015-05-01)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
by: Na Liu, et al.
Published: (2024-12-01)

Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study
by: D. V. Bukhanova, et al.
Published: (2018-12-01)

Epidemiological and etiological characteristics of community-acquired pneumonia in conscripts in the modern period. Comparative evaluation of the effectiveness of pneumococcal vaccines
by: P. V. Kulikov, et al.
Published: (2019-05-01)